metastasis. The mechanistic effectiveness in cell cycle progression, apoptotic induction and gene regulation were assessed for the promising compound 9d due to its remarkable cytotoxic activity against MCF-7 and significant VEGFR-2 inhibition. Flow cytometeric analysis showed that compound 9d induced cell growth cessation at G2/M phase and increased the percentage of cells at pre-G1 phase that stimulates the
合成了新的
噻唑基
吡唑基
香豆素衍
生物,并在体外针对五种不同的人类
细胞系(包括乳腺癌MCF-7,肺A549,前列腺PC3,肝HepG2和正常黑素细胞HFB4)测试了其抗癌潜力。乳腺癌显示出对化合物7a,8c,9b,9c和9d的更高敏感性,与参考药物
阿霉素相比,IC50值在5.41至10.75μM之间(IC50 = 6.73μM)。另外,对正常细胞HFB4没有显示出明显的毒性。此外,对人乳腺癌MCF-7
细胞系中V
EGFR-2抑制作用的体外研究显示,该细胞毒性化合物显示出化合物7a,8c,9b,9c和9d在低微摩尔浓度下是有效的
抑制剂(IC50 = 0.034-0.582 μM)与参考药物
索拉非尼(IC50 = 0.019μM)进行比较。进行了一些理论和实验研究,以揭示控制乳腺癌转移的分子机制。由于其对MCF-7的显着细胞毒活性和对V
EGFR-2的显着抑制作用,对有前途的化合物9d评估了细胞周期进